Remdesivir is a patent in which country?

At the beginning of this year, an epidemic broke out in novel coronavirus. Due to the lack of effective drugs against the virus, clinicians are actively trying other drugs with antiviral activity while routinely treating patients. Although Remdesivir had no previous treatment experience and data for novel coronavirus, it tried to treat novel coronavirus very early because of its antiviral activity. Redixivir is an antiviral drug developed by American Gilead Scientific Group, which is essentially a nucleoside analogue with antiviral activity.

At the end of 1 this year, many papers about novel coronavirus (20 19-nCoV) published online in the New England Journal of Medicine (NEJM) showed that a drug named remdesivir was used in the diagnosis and treatment of the first confirmed case in the United States, and the drug showed good efficacy in anti-novel coronavirus. However, due to the lack of effective data support, it has not been widely promoted.

Therefore, after that, many countries, including the United States and China, began to actively study the role and safety of Remdesivir in the treatment of novel coronavirus patients. Remdesivir's clinical trial has begun.

Up to now, with more and more data on the treatment of patients in novel coronavirus, many countries began to formally use Remdesivir to treat patients in novel coronavirus.

According to the previous statement of the CEO of Gilead Scientific Group, the price of Remdesivir is set at $390 per vial. For most patients, they need to receive ***6 bottles of Remdesivir for 5 days, and the cost is equivalent to $2,340 per patient. This price is very expensive for many families.

On July 2nd, the Korean government decided to put Remdesivir into the treatment of patients with novel coronavirus. And this cost, according to relevant news, is borne by the government in full.